CN1277544C - Composite analgesic composition and its use - Google Patents
Composite analgesic composition and its use Download PDFInfo
- Publication number
- CN1277544C CN1277544C CN 200410044801 CN200410044801A CN1277544C CN 1277544 C CN1277544 C CN 1277544C CN 200410044801 CN200410044801 CN 200410044801 CN 200410044801 A CN200410044801 A CN 200410044801A CN 1277544 C CN1277544 C CN 1277544C
- Authority
- CN
- China
- Prior art keywords
- codeine phosphate
- group
- ibuprofen
- pain
- arginine ibuprofen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 230000000202 analgesic effect Effects 0.000 title claims description 32
- 239000000203 mixture Substances 0.000 title description 4
- 239000002131 composite material Substances 0.000 title 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 claims abstract description 131
- 229960001680 ibuprofen Drugs 0.000 claims abstract description 129
- DKSZLDSPXIWGFO-BLOJGBSASA-N (4r,4ar,7s,7ar,12bs)-9-methoxy-3-methyl-2,4,4a,7,7a,13-hexahydro-1h-4,12-methanobenzofuro[3,2-e]isoquinoline-7-ol;phosphoric acid;hydrate Chemical compound O.OP(O)(O)=O.OP(O)(O)=O.C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC.C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC DKSZLDSPXIWGFO-BLOJGBSASA-N 0.000 claims abstract description 102
- 239000004475 Arginine Substances 0.000 claims abstract description 99
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims abstract description 99
- 229960004415 codeine phosphate Drugs 0.000 claims abstract description 88
- 238000002360 preparation method Methods 0.000 claims abstract description 27
- 239000008194 pharmaceutical composition Substances 0.000 claims description 13
- 239000002775 capsule Substances 0.000 claims description 7
- 239000002552 dosage form Substances 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 230000000694 effects Effects 0.000 abstract description 21
- 150000001875 compounds Chemical class 0.000 abstract description 14
- 230000036592 analgesia Effects 0.000 abstract description 8
- 230000008485 antagonism Effects 0.000 abstract description 8
- 231100000419 toxicity Toxicity 0.000 abstract description 6
- 230000001988 toxicity Effects 0.000 abstract description 6
- 206010012335 Dependence Diseases 0.000 abstract description 3
- 230000002195 synergetic effect Effects 0.000 abstract description 2
- 235000009697 arginine Nutrition 0.000 description 89
- 208000002193 Pain Diseases 0.000 description 66
- 230000036407 pain Effects 0.000 description 66
- 239000003814 drug Substances 0.000 description 37
- 230000008878 coupling Effects 0.000 description 30
- 238000010168 coupling process Methods 0.000 description 30
- 238000005859 coupling reaction Methods 0.000 description 30
- 241000699670 Mus sp. Species 0.000 description 29
- OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 description 29
- 229940079593 drug Drugs 0.000 description 28
- 239000008187 granular material Substances 0.000 description 21
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 16
- 238000012360 testing method Methods 0.000 description 16
- 229920002472 Starch Polymers 0.000 description 14
- 239000008107 starch Substances 0.000 description 14
- 235000019698 starch Nutrition 0.000 description 14
- 238000000034 method Methods 0.000 description 11
- 238000005457 optimization Methods 0.000 description 10
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 9
- OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 description 9
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 9
- 239000008108 microcrystalline cellulose Substances 0.000 description 9
- 229940016286 microcrystalline cellulose Drugs 0.000 description 9
- 238000004445 quantitative analysis Methods 0.000 description 9
- 238000004458 analytical method Methods 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 235000019359 magnesium stearate Nutrition 0.000 description 8
- 239000007779 soft material Substances 0.000 description 8
- PPKXEPBICJTCRU-XMZRARIVSA-N (R,R)-tramadol hydrochloride Chemical compound Cl.COC1=CC=CC([C@]2(O)[C@H](CCCC2)CN(C)C)=C1 PPKXEPBICJTCRU-XMZRARIVSA-N 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 7
- 230000007059 acute toxicity Effects 0.000 description 7
- 231100000403 acute toxicity Toxicity 0.000 description 7
- 229960004126 codeine Drugs 0.000 description 7
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 7
- 239000013641 positive control Substances 0.000 description 7
- TVYLLZQTGLZFBW-ZBFHGGJFSA-N (R,R)-tramadol Chemical group COC1=CC=CC([C@]2(O)[C@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-ZBFHGGJFSA-N 0.000 description 6
- 238000004132 cross linking Methods 0.000 description 6
- 230000003993 interaction Effects 0.000 description 6
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 6
- 239000002002 slurry Substances 0.000 description 6
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 6
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 6
- 230000000638 stimulation Effects 0.000 description 6
- 229960004380 tramadol Drugs 0.000 description 6
- TVYLLZQTGLZFBW-GOEBONIOSA-N tramadol Natural products COC1=CC=CC([C@@]2(O)[C@@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-GOEBONIOSA-N 0.000 description 6
- 238000005516 engineering process Methods 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 206010058019 Cancer Pain Diseases 0.000 description 4
- 206010013786 Dry skin Diseases 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- 208000010513 Stupor Diseases 0.000 description 4
- 239000002671 adjuvant Substances 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 230000000857 drug effect Effects 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 4
- 238000012545 processing Methods 0.000 description 4
- 238000001028 reflection method Methods 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- 206010013710 Drug interaction Diseases 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- 229920000881 Modified starch Polymers 0.000 description 3
- 208000004550 Postoperative Pain Diseases 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 3
- 229940066669 codeine phosphate 6 mg Drugs 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 3
- 239000001253 polyvinylpolypyrrolidone Substances 0.000 description 3
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 3
- 230000005855 radiation Effects 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 230000003637 steroidlike Effects 0.000 description 3
- 238000010998 test method Methods 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- 229960003107 tramadol hydrochloride Drugs 0.000 description 3
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
- 206010011224 Cough Diseases 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 229940035676 analgesics Drugs 0.000 description 2
- 239000000730 antalgic agent Substances 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 229960001012 codeine hydrochloride Drugs 0.000 description 2
- -1 codeine phosphate compound Chemical class 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000012482 interaction analysis Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 229960005181 morphine Drugs 0.000 description 2
- 230000003285 pharmacodynamic effect Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 101800004538 Bradykinin Proteins 0.000 description 1
- 102400000967 Bradykinin Human genes 0.000 description 1
- 206010070840 Gastrointestinal tract irritation Diseases 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 1
- 229930064664 L-arginine Natural products 0.000 description 1
- 235000014852 L-arginine Nutrition 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 102000003840 Opioid Receptors Human genes 0.000 description 1
- 108090000137 Opioid Receptors Proteins 0.000 description 1
- 239000008896 Opium Substances 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Chemical class CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 1
- 102100029469 WD repeat and HMG-box DNA-binding protein 1 Human genes 0.000 description 1
- 101710097421 WD repeat and HMG-box DNA-binding protein 1 Proteins 0.000 description 1
- GCCOJNYCFNSJII-VWMHFEHESA-N [n'-[(4s)-4-amino-4-carboxybutyl]carbamimidoyl]azanium;2-[4-(2-methylpropyl)phenyl]propanoate Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N.CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 GCCOJNYCFNSJII-VWMHFEHESA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000001618 algogenic effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000003907 antipyretic analgesic agent Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000012752 auxiliary agent Substances 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- QXZGBUJJYSLZLT-FDISYFBBSA-N bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229940121657 clinical drug Drugs 0.000 description 1
- 238000010835 comparative analysis Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000007919 dispersible tablet Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 239000002389 essential drug Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229960001027 opium Drugs 0.000 description 1
- 229960005489 paracetamol Drugs 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000036259 sexual stimuli Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
Images
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The present invention relates to the field of medical preparations, and discloses a compound preparation containing arginine ibuprofen and codeine phosphate and an application thereof. The arginine ibuprofen and the codeine phosphate have a synergistic effect on treating effects, and have the toxicity which has antagonism performance. The present invention is the compound analgesia preparation of rapid and strong effect and low addiction.
Description
Technical field
The present invention relates to field of pharmaceutical preparations, disclose compound preparation that contains arginine Ibuprofen and codeine phosphate and uses thereof.
Background technology
Pain is the numerous disease clinical symptoms, is come to harm a kind of protective response of sexual stimulus of body.
Analgesic is divided into two big classes, act on central nervous system's narcosis analgesic and the non-steroidal anti-inflammatory analgesics (NSAID) that acts on peripheral-system, central analgesics has very strong analgesic activity, but because of its side effect is big, especially easily addiction and limited its application.That the non-steroidal anti-inflammatory analgesics is that a class has is analgesic, the medicine of analgesia and antiinflammatory action, is the essential drugs of treatment pain, and analgesic activity is weaker than the former, but side effect is relatively little, is considered to a line choice drug in treatment in the slight and moderate pain.
Codeine phosphate is a narcosis analgesic, bring into play analgesic activity by the opiate receptor that acts on the central nervous system, belong to weak opium kind analgesics, its analgesic effect is the 1/7-1/10 of morphine, but be better than general antipyretic analgesic, and can directly suppress coughing centre, be used for cough-relieving and analgesia in clinical.In the cancer pain treatment, be the main medicine of second ladder of three grades of pain relieving rescue by stages of cancer of Ministry of Public Health promulgation.
The NSAID ibuprofen is a kind of propanoic acid analog derivative, its raw material and preparation record in Chinese Pharmacopoeia, and with other NSAID-sample, ibuprofen acts on periphery, by suppressing the synthetic of prostaglandin, reduction is organized the sensitivity of histamine, 5-hydroxy tryptamine, this class algogenic substance of Kallidin I is worked.Curative effect is equal to aspirin, is better than acetaminophen, and its side effect is little, and especially gastrointestinal irritation and hepatorenal damage are little, take for a long time, and good tolerability is arranged.Ibuprofen is several water insoluble, oral easy absorption, blood concentration peak time (T
Max) be 1.5-2h, half-life (t
1/2) be 2 hours, the same with other oral NSAID, onset is slower relatively.
Arginine Ibuprofen is a kind of new salt of ibuprofen and L-arginine be combined into.Be the non-steroidal anti-inflammatory analgesics.Because arginic combination, changed the water-insoluble of ibuprofen, made it make various water soluble preparations, although physical behavior changes according to clinical needs, but still kept the pharmacological action characteristic of ibuprofen behind ibuprofen and the arginine salify, its drug action and ibuprofen are suitable.(China Pharmacist 1999，Vol.2 No.1 p8～9)
Moderate pain is clinical common symptom, and patient is large in number and widely distributed, as various postoperative pain, cancer pain etc., for this class case, it is not enough using NSAID class medicine analgesic effect, usually need to use narcosis analgesic, but because of often needing repeat administration easily to produce dependency.In clinical analgesia, often with two class analgesic administering drug combinations, to strengthen analgesic effect, reduce the dosage of narcosis analgesic, especially reduce the use amount of strong dependency medicines such as morphine, at present this class compound preparation of listing has that naphthalene is general to be treated because of, ibuprofen and codeine etc., and the compound preparation that ibuprofen and codeine is made up of ibuprofen and codeine phosphate is widely used in clinical.But need clinical more quick acting, better, the littler medicine of side effect of analgesic effect of needing for treatment.
Summary of the invention
The object of the invention provides a kind of quick-acting, potent and low addiction compound pain preparation.This compound preparation is applicable to the pain relieving of moderate cancer pain and postoperative pain.
Compound pain preparation of the present invention is the compound preparation that active component is formed by arginine Ibuprofen and codeine phosphate.
Concrete scheme of the present invention is:
A kind of pharmaceutical composition is made up of arginine Ibuprofen, codeine phosphate and pharmaceutically acceptable carrier.
Wherein the weight ratio of arginine Ibuprofen and codeine phosphate preferred 14～45: 1.
More preferably 25～32: 1.
More preferred weight ratio is 28～29: 1.
Highly preferred weight ratio is 28.5: 1.
Pharmaceutically acceptable carrier is meant one or more inert, avirulent solid or liquid filler material, auxiliary agents etc., and their not reverse and reactive compounds or patient have an effect.
The dosage form of the present composition can be commonly used through the intestinal dosage form on the pharmaceuticss such as tablet, capsule, pill, dispersible tablet, granule, powder.
Tablet for oral use and capsule contain traditional excipient such as diluent, lubricant, dispersant and binding agent.
The dosage of above activating agent will be different because of prescription.Through the quantitative analysis and the prescription optimization of arginine Ibuprofen and codeine phosphate analgesic activity, when arginine Ibuprofen is 60～347mg/kg, codeine phosphate is 2.1～12mg/kg, and analgesic activity shows as obvious synergistic; When arginine Ibuprofen is 85～170mg/kg, synergism was particularly evident when codeine phosphate was 3～6mg/kg.Learn in the test, arginine Ibuprofen and codeine phosphate weight ratio preferable range are 13.6～44.6: 1, the theoretical optimization prescription is arginine Ibuprofen 170mg/kg+ codeine phosphate 6mg/kg, weight ratio is 28.33: 1, according to this pharmacological tests, in the preparation oral formulations, the weight that preferably contains arginine Ibuprofen and codeine phosphate in the per unit preparation is 370mg: 8-27mg; 370mg: 8-15mg more preferably; The optimum weight proportioning is 370mg: 13mg.Described " per unit preparation " is meant: if tablet just refers to a tablet, the rest may be inferred.
Pharmaceutical composition of the present invention can be used for analgesia clinically, mainly is to be used for pain relieving of moderate cancer pain and postoperative pain.
In to compound preparation pharmacology test of the present invention, be surprised to find, arginine Ibuprofen and codeine phosphate compound preparation drug effect have concertedness, toxic and side effects has antagonism, clinical application has more safety, compare with ibuprofen and codeine (ibuprofen+codeine phosphate), onset is rapid, and analgesic effect is stronger, has reached unexpected effect.
Be part pharmacology test of the present invention and data below:
One, arginine Ibuprofen, codeine phosphate associating analgesic activity quantitative analysis and prescription optimization
1 purpose
Inquire into different proportion arginine Ibuprofen and codeine phosphate coupling,, and determine its optimization composition of prescription the inhibitory action of mice radiant heat stimulation pain model.
2 methods
2.1 experiment grouping and dosage setting
Mice fasting 8h is the mice group of 10 ± 2 seconds (s) with the basic threshold of pain of screening, is divided into 7 groups at random, 10 every group, and male and female half and half.Wherein 6 groups is the medication group of different proportionings, and 1 group is 0.9% normal saline matched group in addition.Each is organized medication (single gastric infusion) capacity and is the 0.2ml/10g body weight.According to preliminary experiment and with reference to external similar clinical drug prescription dosage, determine capacity and weak effect amount, i.e. the prescription dosage range of each component: arginine Ibuprofen 13-170mg/kg and codeine phosphate are 1.4-6mg/kg.Two medicines with 0.6,0.75 ratio, are arranged serial dosage respectively, and the dosage range that makes each medicine is between capacity and weak effect amount.By the design of weight method of completing the square, each dosage is evenly distributed to 6 compatibility groups (table 1).
The recipe design of table 1 arginine Ibuprofen and codeine phosphate (mg/kg)
| The compatibility group | Arginine Ibuprofen (D1) | Codeine phosphate (D2) |
| 1 | 13(1) | 2.5(3) |
| 2 | 22(2) | 6.0(6) |
| 3 | 37(3) | 1.9(2) |
| 4 | 61(4) | 4.5(5) |
| 5 | 102(5) | 1.4(1) |
| 6 | 170(6) | 3.8(4) |
| x | 67.5 | 3.35 |
| D max | 170 | 6 |
| | 13 | 1.4 |
In () is the serial number of dosage level; D
MaxBe the high limit of prescription dosage range, D
MinBe lower bound.
2.2 experimental technique
Keep 20 ℃ of room temperatures, mice is packed in the stationary magazine creel, outside afterbody was exposed to, following 1/3 place of afterbody was as the photostimulation point.Begin incubation period (TFL) to whipping reaction as the threshold of pain from irradiation.Before administration, measure 3 times earlier, each 5min at interval, getting its average is the basic threshold of pain.The different periods after the administration (10,20,30,40,60 and 120min) are measured the threshold of pain respectively.If the threshold of pain be elevated to 2 times of the basic threshold of pains not whipping promptly interrupt irradiation, in order to avoid scalded skin, and with the 2 times of calculating in the basic threshold of pain.
2.3 definitiveness test
Based on above experimental result, try to achieve the theoretical optimization prescription according to the weight method of completing the square, comprise coupling dosage, coupling ratio, test is confirmed again.20 of mices are divided into 2 groups at random by body weight, sex, 10 every group.One group is the theoretical optimization prescription, and another group is for the prescription of ceiling effect occurring.Experimental technique and observation index are the same, to determine optimum prescription.
2.4 date processing
Threshold of pain raising rate=((TFL-basis TFL after the administration)/basic TFL) * 100%
Data mean ± standard deviation (x ± s) expression, drug interaction analysis is finished by DAS (ver1.0) software; The group difference significance analysis is checked with t.
3 results
3.1 the different compatibility groups of arginine Ibuprofen and codeine phosphate are to the influence of the mice 30min threshold of pain
Each observes 120min after organizing the mice medication continuously, and the threshold of pain raising rate of each group is all greater than normal saline group (P＜0.01).Maximum threshold of pain raising rate all appears in each compatibility group when 30min, maximum actual measurement effect group (Gmax) is a compatibility group 6, sees Table 2.Each compatibility group markization compatibility dosage (d) and effect thereof see Table 3.
Raising rate in the 30min threshold of pain after table 2 medication
| The compatibility group | The dosage (mg/kg) of each component in the compatibility group | Threshold of pain raising rate (%) (x ± s) | |
| Codeine | Arginine Ibuprofen | ||
| 1 | 2.5 | 13 | 37.08±13.36 |
| 2 | 6 | 22 | 64.02±16.36 |
| 3 | 1.9 | 37 | 40.89±15.90 |
| 4 | 4.5 | 61 | 72.25±16.78 |
| 5 | 1.4 | 102 | 50.41±15.24 |
| 6 | 3.8 | 170 | 74.33±22.56 |
The mark dosage (di) of table 3 arginine Ibuprofen and codeine phosphate and mutual (didj) thereof
Relation with coupling drug effect (threshold of pain raising rate %)
| Group | d1 | d2 | d1d2 | Threshold of pain raising rate (x ± s) |
| 1 | 0.746 | 0.193 | 0.144 | 37.08±13.36 |
| 2 | 1.791 | 0.326 | 0.584 | 64.02±16.36 |
| 3 | 0.567 | 0.548 | 0.311 | 40.89±15.9 |
| 4 | 1.343 | 0.904 | 1.214 | 72.25±16.78 |
| 5 | 0.418 | 1.511 | 0.632 | 50.41±15.24 |
| 6 | 1.134 | 2.519 | 2.857 | 74.33±22.56 |
D is the mean of each compatibility dosage divided by its column dosage
3.2 arginine Ibuprofen and codeine phosphate coupling are to the inhibiting quantitative analysis of mice radiant heat stimulation pain model
Maximum threshold of pain raising rate all appears in each compatibility group when 30min, thus with the threshold of pain raising rate of 30min after the medication as analysis indexes, with the input of the data in the table 2 DAS software, analyze result's following (seeing accompanying drawing 1) with the weight method of completing the square:
A. two medicines are in uniting analgesia, its significance level codeine phosphate＞arginine Ibuprofen.
B. two medicines coupling in the dosage range that table 1 sets, arginine Ibuprofen has synergism (P＜0.05) to codeine phosphate.
C. the theoretical optimization prescription is: codeine phosphate 6mg/kg+ arginine Ibuprofen 170mg/kg, the coupling ratio is 1: 28.33.
3.3 definitiveness test
Experimental result sees Table 4.Theoretical optimization prescription and the prescription (G that ceiling effect occurs
Max) the 30min threshold of pain raising rate and the no difference of science of statistics of (in the table 2 the 6th group), but 60, the threshold of pain raising rate of 120min theoretical optimization group is all greater than G
MaxGroup (P＜0.05).
Table 4 definitiveness two kinds of unitized doses of test (mg/kg) are to mice radiant heat stimulation pain model inhibitory action
| Group | n | Codeine phosphate | Ibuprofen arginine | Threshold of pain raising rate (%) | ||
| 30min | 60min | 120min | ||||
| | 10 | 3.8 | 170 | 70.58±23.02 | 42.48±15.59 | 21.46±14.43 |
| The | 10 | 6 | 170 | 75.66±19.26 | 59.90±18.28 | 33.92±10.75 |
4 conclusions
Arginine Ibuprofen and codeine phosphate use in conjunction are according to the analgesic activity that the mice radiant heat is stimulated, its significance level codeine phosphate＞arginine Ibuprofen.Arginine Ibuprofen has synergism to codeine phosphate.Optimum prescription is: arginine Ibuprofen 170mg/kg+ codeine phosphate 6mg/kg, the coupling ratio is 28.33: 1.
Two, the analgesic activity of arginine Ibuprofen, codeine phosphate coupling and independent medication respectively and interaction dosage range is quantitative
Analyze
1 purpose
Relatively arginine Ibuprofen, codeine phosphate coupling and the inhibitory action of the independent medication of difference to mice radiant heat stimulation pain model.Carry out quantitative analysis with reflection method, determine effective therapeutic dose scope.
2 methods
2.1 experiment grouping and dosage setting
Mice fasting 8h is 10 ± 2 seconds a mice group with the basic threshold of pain of screening, is divided into 21 groups at random, and 10 every group, male and female half and half are arranged serial dosage with 0.7 ratio, and the dosage setting sees Table 5.
Table 5 arginine Ibuprofen, codeine phosphate coupling and singly use test dose setting (mg/kg) to the mice analgesic activity
| Arginine Ibuprofen group mg/kg | Codeine phosphate group mg/kg | Arginine Ibuprofen+codeine phosphate (28.33: 1) group | |
| Arginine Ibuprofen (mg/kg) | Codeine phosphate (mg/kg) | ||
| 41 | 1.4 | 41 | 1.4 |
| 58 | 2.1 | 58 | 2.1 |
| 83 | 2.9 | 83 | 2.9 |
| 119 | 4.2 | 119 | 4.2 |
| 170 | 6.0 | 170 | 6.0 |
| 243 | 8.6 | 243 | 8.6 |
| 347 | 12.2 | 347 | 12.2 |
2.2 test method
Optimize item test method down with quantitative analysis and prescription.
2.3 date processing
Threshold of pain raising rate=((TFL-basis TFL after the administration)/basic TFL) * 100%
(x ± s) expression, drug interaction analysis carries out statistical disposition by DAS software by reflection method to data with mean ± standard deviation.
3 results
Each is organized and observes 120min after the mice medication continuously, and maximum threshold of pain raising rate all appears in each group when 30min, thus with the threshold of pain raising rate of 30min after the medication as analysis indexes.Each is organized dosage and effect thereof and sees Table 6, two drug interactions and carry out quantitative analysis by reflection method, the results are shown in Figure 2.
4 conclusions
Arginine Ibuprofen and codeine phosphate coupling show as concertedness to the analgesic activity of mice radiant heat stimulation pain model.At arginine Ibuprofen 85-170mg/kg and codeine phosphate 3-6mg/kg, synergism is (Q＞2) particularly significantly.
Table 6 arginine Ibuprofen and codeine phosphate list with and coupling to the analgesic activity of mice (x, n=10)
| The arginine Ibuprofen group | The codeine phosphate group | Arginine Ibuprofen+codeine phosphate group | ||||
| mg/kg | Threshold of pain raising rate (%) | mg/kg | Threshold of pain raising rate (%) | Arginine Ibuprofen mg/kg | Codeine phosphate mg/kg | Threshold of pain raising rate (%) |
| 43 | 17.02 | 1.5 | 0.03 | 43 | 1.5 | 18.9 |
| 60 | 20.64 | 2.1 | 3.52 | 60 | 2.1 | 28.24 |
| 85 | 30.35 | 3.0 | 1.31 | 85 | 3.0 | 35.84 |
| 120 | 36.41 | 4.2 | 0.26 | 120 | 4.2 | 49.6 |
| 170 | 53.17 | 6.0 | 1.34 | 170 | 6.0 | 74.73 |
| 243 | 48.21 | 8.6 | 2.55 | 243 | 8.6 | 71.92 |
| 347 | 43.4 | 12.0 | 14.32 | 347 | 12.0 | 56.21 |
Three, arginine Ibuprofen, codeine phosphate coupling are to the quantitative analysis of chmice acute toxic action
1 purpose
Observe arginine Ibuprofen, the codeine phosphate coupling changes (strengthen, weaken or do not become) to chmice acute toxicity, many acute toxicities angle is determined the reasonability of prescription.
2 experimental techniques
Mice fasting 8h gets 150, and male and female half and half are divided into 15 groups at random, 10 every group.According to the preliminary experiment result, press LD
50Assay method is provided with the serial dosage (seeing Table 7) of two prescriptions usefulness and coupling.The administration volume is the 0.2ml/10g body weight.Observe after the disposable mouse stomach administration each dosage treated animal death condition in 7 days.
The anxious malicious test dose setting of the mice of table 7 arginine Ibuprofen and codeine phosphate list usefulness and coupling
| The dosage group | Arginine Ibuprofen group (mg/kg) | Codeine phosphate group (mg/kg) | Arginine Ibuprofen+codeine phosphate group | |
| Arginine Ibuprofen (mg/kg) | Codeine phosphate (mg/kg) | |||
| 1 | 2343 | 625 | 2667 | 94 |
| 2 | 1875 | 500 | 2000 | 71 |
| 3 | 1500 | 400 | 1500 | 53 |
| 4 | 1200 | 320 | 1125 | 40 |
| 5 | 960 | 256 | 844 | 30 |
2 date processing
Gained data input DAS software carries out statistical disposition by parametric method.
3 results
Arginine Ibuprofen and codeine phosphate two components are single with seeing Table 8～10 with coupling animal dead rate.The analysis showed that through parametric method: arginine Ibuprofen and codeine phosphate were in ratio coupling in 28.33: 1, in the dosage range of being analyzed, through the interaction dynamics analysis of two medicine coupling acute toxicities, Q-value is the 0.48--2.68 scope, (Q＜-1 is an antagonism, and promptly toxicity reduces; Q＞1 is a synergism, and promptly toxicity strengthens;-1≤Q≤1 is an additivity, and promptly toxicity does not increase), the acute toxicity of two medicine couplings is antagonism or additivity, i.e. acute toxicity effect descends or does not increase (seeing Table 11).
The table 8 codeine phosphate list animal dead rate of (ig)
| Group | Codeine phosphate (mg/kg) | Log10 dose (lgd) | Mortality rate (p) | P 2 | Probit |
| 1 | 625 | 2.7959 | 1.0 | 1.00 | 6.96 |
| 2 | 500 | 2.6990 | 0.8 | 0.64 | 5.84 |
| 3 | 400 | 2.6021 | 0.5 | 0.25 | 5.00 |
| 4 | 320 | 2.5051 | 0.3 | 0.09 | 4.48 |
| 5 | 256 | 2.4082 | 0.0 | 0.00 | 3.04 |
The table 9 arginine Ibuprofen list animal dead rate of (ig)
| Group | Arginine Ibuprofen (mg/kg) | Log10 dose (lgd) | Mortality rate (p) | P 2 | Probit |
| 1 | 2343 | 3.3698 | 1 | 1 | 6.96 |
| 2 | 1875 | 3.2730 | 0.8 | 0.64 | 5.84 |
| 3 | 1500 | 3.1761 | 0.3 | 0.09 | 4.48 |
| 4 | 1200 | 3.0792 | 0.2 | 0.04 | 4.16 |
| 5 | 960 | 2.9823 | 0 | 0 | 3.04 |
Table 10 arginine Ibuprofen and codeine phosphate coupling (28.33: 1, animal dead rate ig)
| Group | Arginine Ibuprofen+codeine phosphate group | The logarithm value of two pharmaceutical quantities sums | Mortality rate (p) | P 2 | Probit | |
| Arginine Ibuprofen (mg/kg) | Codeine phosphate (mg/kg) | |||||
| 1 | 2667 | 94 | 3.44 | 0.9 | 0.81 | 6.28 |
| 2 | 2000 | 71 | 3.32 | 0.5 | 0.25 | 5.00 |
| 3 | 1500 | 53 | 3.19 | 0.3 | 0.09 | 4.48 |
| 4 | 1125 | 40 | 3.07 | 0.2 | 0.04 | 4.16 |
| 5 | 844 | 30 | 2.94 | 0.1 | 0.01 | 3.72 |
Table 11 arginine Ibuprofen and codeine phosphate coupling (mg/kg, the quantitative analysis of anxious toxic action ig)
| Arginine Ibuprofen | Codeine phosphate | The actual measurement mortality rate | Corrected mortality | The expectation mortality rate | Q-value | The coupling result |
| 844 | 30 | 0.100 | 0.055 | 0.006 | 0.48 | + |
| 1125 | 40 | 0.200 | 0.143 | 0.056 | 0.86 | + |
| 1500 | 53 | 0.300 | 0.325 | 0.367 | -0.43 | + |
| 2000 | 71 | 0.500 | 0.582 | 0.849 | -2.68 | - |
| 2667 | 94 | 0.900 | 0.801 | 0.982 | -1.82 | - |
-expression Q-value＜-1 belongs to antagonism interaction (toxicity reduction), and+expression Q refers between 1 and-1, symbolic animal of the birth year additivity interaction (toxicity does not increase).
4 conclusions
The mice LD of arginine Ibuprofen list time spent
50Be 1560.5mg/kg (ig) the mice LD of codeine phosphate list time spent
50Be 391.1mg/kg (ig).Arginine Ibuprofen and codeine phosphate are in the mice LD of ratio coupling in 28.33: 1
50Be 1824.0mg/kg (ig).Analysis-by-synthesis is at LD
50On the point, two medicine couplings present antagonism.By Different L D
kContrast, press the Q-value method and calculate, in the scope (in 28.33: 1 ratios) of arginine Ibuprofen 844-2667mg/kg+ codeine phosphate 30-94mg/kg, antagonism and additivity appear in the acute toxicity of two medicine couplings, i.e. acute toxicity effect decline or do not increase.Four, the pharmacodynamics test of arginine Ibuprofen, codeine phosphate coupling analgesic activity
1 purpose
The arginine Ibuprofen, codeine phosphate of the various dose inhibitory action to mice radiant heat stimulation pain model is inquired in this test, and carry out drug effect with ibuprofen and codeine and tramadol hydrochloride and compare, ibuprofen and codeine is ibuprofen and codeine phosphate compound preparation, the domestic listing kind that different proportionings are arranged, get the ibuprofen and codeine of suitable dosage ratio, carry out drug effect relatively with this compound preparation.
2 methods
2.1 grouping and dosage setting
Mice fasting 8h is 10 ± 2 seconds animal grouping with the basic threshold of pain of screening, is divided into 7 groups at random, 10 every group, and male and female half and half.Result of the test according to above weight method of completing the square and reflection method, getting arginine Ibuprofen 240mg/kg+ codeine phosphate 8.5mg/kg is high dose, in, low dose group successively decreases in 0.5 ratio, as positive control, each is organized drug dose and is provided with as follows with ibuprofen and codeine and tramadol hydrochloride:
1 blank group: 25-37 ℃ normal saline
2 tramadol groups: tramadol hydrochloride, 15mg/kg (according to the conversion of human dosage) ig.
3 ibuprofen and codeine groups: ibuprofen and codeine 69.2mg/kg (ibuprofen 65mg/kg+ codeine phosphate 4.2mg/kg), ig.
4 low dose group: arginine Ibuprofen 60mg/kg+ codeine phosphate 2.1mg/kg, ig.
Dosage group in 5: arginine Ibuprofen 120mg/kg+ codeine phosphate 4.2mg/kg, ig.
6 high dose group: arginine Ibuprofen 240mg/kg+ codeine phosphate 8.5mg/kg, ig.
Each is organized medication (single gastric infusion) capacity and is the 0.2ml/10g body weight.
2.2 experimental technique
Optimize item test method down with quantitative analysis and prescription.After administration 10,20,30,60,120,180 and 240min measure the threshold of pain respectively.
3 date processing
Threshold of pain raising rate=((TFL-basis TFL after the administration)/basic TFL) * 100%
Area (AUC) calculates with trapezoidal method under threshold of pain raising rate-time graph.Data mean ± standard deviation (x ± s) expression, pharmacodynamic analysis is finished by DAS software; The group difference significance analysis is checked with t; ED
50Use the NDST computed in software.
4 results
Arginine Ibuprofen and codeine phosphate coupling stimulate the time-histories variation of model analgesic activity to see Fig. 3,4 to the mice radiant heat.Result of the test shows: (1) arginine Ibuprofen+codeine phosphate gastric infusion, high, middle dosage group 10min after administration begins, threshold of pain raising rate obviously increases (P＜0.05, P＜0.01vs blank group), low dose group 30min after administration begins, and threshold of pain raising rate obviously increases (P＜0.05vs blank group); Tramadol group and ibuprofen and codeine group respectively after administration 20min and 60min begin to occur tangible threshold of pain raising rate and increase (P＜0.05, P＜0.01vs blank group).(2) threshold of pain raising rate (%) of 30min arginine Ibuprofen+codeine phosphate group reaches maximum after the administration, and the increase degree is dose-dependence, wherein high dose group is 68.20 ± 17.51 (P＜0.01vs blank group), tramadol group and ibuprofen and codeine group all threshold of pain raising rate maximum occurs at 60min, are respectively 38.12 ± 17.05 and 24.26 ± 15.42 (P＜0.01vs blank group).(3) arginine Ibuprofen+codeine phosphate height, middle dosage group still can obviously improve threshold of pain raising rate (P＜0.01, P＜0.05vs blank group) at administration 180min; Tramadol group and ibuprofen and codeine group in 180min threshold of pain raising rate also apparently higher than blank group (P＜0.05).
As seen from Table 12, area (AUC) is all significantly greater than blank group (P＜0.01) under the threshold of pain raising rate-time graph of tramadol group, ibuprofen and codeine group and height, middle dosage arginine Ibuprofen+codeine phosphate group, high dose group is higher than tramadol hydrochloride group and ibuprofen and codeine group (difference P＜0.05, P＜0.01), middle dosage group and two positive control drug zero differences.Maximum threshold of pain raising rate (E
Max) relatively go up, high, middle dosage arginine Ibuprofen+codeine phosphate group and two positive control drugs all are significantly higher than blank group (P＜0.01), the effect of high dose group is better than two positive control drug groups (P＜0.01), and the effect of middle dosage group is better than ibuprofen and codeine group (P＜0.05).
Fragrant arginine+the codeine phosphate in table 12 Lip river (ig) is to mice thermal radiation model threshold of pain raising rate-time graph
Following area (AUC) and maximum threshold of pain raising rate (E
Max) influence (n=10, x ± s)
| Group | Dose(mg/kg) | AUC(％·min) | E max(％) |
| ①Normal | NS | 228.34±1130.64 | 18.03±10.15 |
| ②Tramadol | Tramadol 15 | 4365.56±1709.5 c | 42.45±16.57 c |
| ③Ibu+Cod | Ibu 65+Cod 4.3 | 3120.35±1866.39 c | 32.85±12.96 b |
| ④Is+Cod | Is 60+Cod 2.1 | 1265.35±1159.03 fk | 23.63±14.44 e |
| ⑤Is+Cod | Is 120+Cod 4.3 | 3736.18±1726.41 c | 49.06±15.35 ck |
| (⑥)Is+Cod | Is 240+Cod 8.5 | 6805.36±2347.06 cel | 68.20±17.51 cfl |
Annotate:
bP＜0.05,
cP＜0.01vs Group 1.;
eP＜0.05,
fP＜0.01vs Group 2.;
kP＜0.05;
lP＜0.01vs Group is 3..
5 conclusions
Experimental result shows, arginine Ibuprofen+codeine phosphate group stimulates model to have significant analgesia role to the mice radiant heat, in 10～180min, obviously increase threshold of pain raising rate, area (AUC) under maximum threshold of pain raising rate and the threshold of pain raising rate-time graph, and analgesic activity is dose dependent.Arginine Ibuprofen+codeine phosphate group can produce significant analgesia role behind administration 10min, and about 30min, produce maximum analgesic activity, all (be respectively 20min early than the tramadol hydrochloride group, 60min) (be respectively 60min with the ibuprofen and codeine group, 60min), in arginine Ibuprofen+codeine phosphate the dosage group 20 and during 30min threshold of pain raising rate apparently higher than two positive control drugs (P＜0.01).Test the onset time of the analgesic activity that shows arginine Ibuprofen+codeine phosphate and reach the peak all faster than two positive control drugs.Maximum threshold of pain raising rate (E
Max) relatively go up, middle dosage group is higher than the ibuprofen and codeine group, high dose group is higher than tramadol hydrochloride group and ibuprofen and codeine group.The AUC value compares, and high dose group is higher than tramadol hydrochloride group and ibuprofen and codeine group, middle dosage group and two positive control drug zero differences.Holding time of the analgesic activity of arginine Ibuprofen+codeine phosphate group is similar to two positive drug, is 180min.Test prompting compound preparation analgesic activity is better than ibuprofen and codeine.
Description of drawings
(d1, d2 are markization dosage with 30min threshold of pain raising rate relation (dose-effect relationship) for Fig. 1 arginine Ibuprofen (d1), codeine phosphate (d2) and mutual item (d1d2) thereof, promptly a component dosage is sentenced its mean, cancel its unit, its data character is constant, but is convenient to comparative analysis)
The interaction dynamics analysis of Fig. 2 arginine Ibuprofen and codeine phosphate coupling (28.33: 1).Q-value on the Q=1 line represents that concertedness interacts, and the Q-value between the dotted line is that additivity interacts, and the following Q-value of Q=-1 line is represented the antagonism interaction
Fig. 3 arginine Ibuprofen+codeine phosphate (ig) is to the preclinical influence of mice thermal radiation model pain
Fig. 4 arginine Ibuprofen+codeine phosphate (ig) is to the influence of mice thermal radiation model threshold of pain raising rate
The specific embodiment
Prescription:
Arginine Ibuprofen 370 grams
Starch 69 grams
Cross-linking sodium carboxymethyl cellulose 15 grams
Magnesium stearate 2.5 grams
7%PVP solution 10.5 grams
1000 of fills
Preparation technology:
Medicine and adjuvant are crossed 80 mesh sieves respectively, arginine Ibuprofen is fully mixed with 49 gram starch and 13 gram cross-linking sodium carboxymethyl celluloses, 7%PVP solution system soft material, 18 mesh sieves are granulated, and 60 ℃ of dryings down get granule 1.Codeine phosphate and 20 gram lactose, 20 gram starch and 2 gram cross-linking sodium carboxymethyl celluloses are fully mixed, and 7%PVP solution system soft material, 18 mesh sieves are granulated, and 60 ℃ dry down, gets granule 2.Increase progressively principle by equivalent, granule 1 and granule 2 are fully mixed, 16 mesh sieve granulate add magnesium stearate, mixing, encapsulating capsule, the heavy 500mg of capsule.
Prescription:
Arginine Ibuprofen 370 grams
Microcrystalline Cellulose 52 grams
Pregelatinized Starch 42 grams
Cross-linking sodium carboxymethyl cellulose 15 grams
Magnesium stearate 2.5 grams
10% starch slurry, 5.5 grams
Suppress 1000
Preparation technology:
Medicine and adjuvant are crossed 80 mesh sieves respectively, arginine Ibuprofen is fully mixed with 34 gram microcrystalline Cellulose, 30 gram pregelatinized Starch and 13 gram cross-linking sodium carboxymethyl celluloses, 10% starch slurry system soft material, 18 mesh sieves are granulated, and 60 ℃ of dryings down get granule 1.Codeine phosphate and 18 gram microcrystalline Cellulose, 12 gram pregelatinized Starch and 2 gram cross-linking sodium carboxymethyl celluloses are fully mixed, and 10% starch slurry system soft material, 18 mesh sieves are granulated, and 60 ℃ dry down, gets granule 2.Increase progressively principle by equivalent, granule 1 and granule 2 are fully mixed, 16 mesh sieve granulate add magnesium stearate, mixing, tabletting, the heavy 500mg of sheet.
Prescription:
Arginine Ibuprofen 370 grams
Codeine phosphate 8 grams
Microcrystalline Cellulose 71 grams
Lactose 23 grams
Polyvinylpolypyrrolidone 15 grams
Magnesium stearate 2.5 grams
7%PVP solution 10.5 grams
1000 of fills
Preparation technology:
Medicine and adjuvant are crossed 80 mesh sieves respectively, arginine Ibuprofen is fully mixed with 56 gram microcrystalline Cellulose and 13 gram polyvinylpolypyrrolidone, 7%PVP solution system soft material, 18 mesh sieves are granulated, and 60 ℃ of dryings down get granule 1.Codeine phosphate and 23 gram lactose, 15 gram microcrystalline Cellulose and 2 gram polyvinylpolypyrrolidone are fully mixed, and 7%PVP solution system soft material, 18 mesh sieves are granulated, and 60 ℃ dry down, gets granule 2.Increase progressively principle by equivalent, granule 1 and granule 2 are fully mixed, 16 mesh sieve granulate add magnesium stearate, mixing, encapsulating capsule, the heavy 500mg of capsule.
Embodiment 4
Arginine Ibuprofen 370 grams
Codeine phosphate 15 grams
Microcrystalline Cellulose 72 grams
Starch 15 grams
Magnesium stearate 2.5 grams
10% starch slurry, 5.5 grams
Suppress 1000
Preparation technology:
Medicine and adjuvant are crossed 80 mesh sieves respectively, arginine Ibuprofen is fully mixed with 60 gram microcrystalline Cellulose and 18 gram carboxymethyl starch sodium, 10% starch slurry system soft material, 18 mesh sieves are granulated, and 60 ℃ of dryings down get granule 1.Codeine phosphate and 12 gram microcrystalline Cellulose, 15 gram starch and 2 gram carboxymethyl starch sodium are fully mixed, and 10% starch slurry system soft material, 18 mesh sieves are granulated, and 60 ℃ dry down, gets granule 2.Increase progressively principle by equivalent, granule 1 and granule 2 are fully mixed, 16 mesh sieve granulate add magnesium stearate, mixing, tabletting, the heavy 500mg of sheet.
Claims (10)
1, a kind of pharmaceutical composition is characterized in that: be made up of arginine Ibuprofen, codeine phosphate and pharmaceutically acceptable carrier.
2, the pharmaceutical composition of claim 1, the weight ratio that it is characterized in that arginine Ibuprofen and codeine phosphate is 14～45: 1.
3, the pharmaceutical composition of claim 2, the weight ratio that it is characterized in that arginine Ibuprofen and codeine phosphate is 25～32: 1.
4, the pharmaceutical composition of claim 3, the weight ratio that it is characterized in that arginine Ibuprofen and codeine phosphate is 28～29: 1.
5, the pharmaceutical composition of claim 4, the weight ratio that it is characterized in that arginine Ibuprofen and codeine phosphate is 28.5: 1.
6, each pharmaceutical composition in the claim 1 to 5, its dosage form is tablet or capsule.
7, the pharmaceutical composition of claim 5 wherein contains arginine Ibuprofen 370mg, codeine phosphate 8～27mg in the per unit preparation.
8, the pharmaceutical composition of claim 7 wherein contains arginine Ibuprofen 370mg, codeine phosphate 8～15mg in the per unit preparation.
9, the pharmaceutical composition of claim 8 wherein contains arginine Ibuprofen 370mg, codeine phosphate 13mg in the per unit preparation.
10, each pharmaceutical composition is used to prepare the purposes of analgesic in the claim 1 to 9.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200410044801 CN1277544C (en) | 2004-06-02 | 2004-06-02 | Composite analgesic composition and its use |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200410044801 CN1277544C (en) | 2004-06-02 | 2004-06-02 | Composite analgesic composition and its use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1582948A CN1582948A (en) | 2005-02-23 |
| CN1277544C true CN1277544C (en) | 2006-10-04 |
Family
ID=34601754
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200410044801 Expired - Lifetime CN1277544C (en) | 2004-06-02 | 2004-06-02 | Composite analgesic composition and its use |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1277544C (en) |
-
2004
- 2004-06-02 CN CN 200410044801 patent/CN1277544C/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| CN1582948A (en) | 2005-02-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101073563A (en) | Chiral composition containing dextrothyroxine buprofenli and levomethadyl cysteliqin and its double slow-releasing tablet | |
| CN1686458A (en) | Chinese medicinal composition, its preparation method and use | |
| CN1939521A (en) | Medicine for treating gout | |
| CN1943564A (en) | Indapamide slow release tablet and its preparing method | |
| CN1813819A (en) | Hedgehog hydnum fruiting body or hyphostroma and culture extract and formulation and preparing method | |
| CN1857362A (en) | Jingankang medicine preparation and its preparing process | |
| CN1927331A (en) | Chinese medicine preparation for curing chronic heart failure | |
| CN1277544C (en) | Composite analgesic composition and its use | |
| CN1610548A (en) | Use of irbesartan for the preparation of medicaments that are used to prevent or treat pulmonary hypertension | |
| CN101028518A (en) | Medicinal composition containing silver ester medicine and ibobulodine | |
| CN100335090C (en) | Medicinal composition for tonifying kidney and eliminating obstruction, and its preparing method | |
| CN1500487A (en) | Oral compound levocetirizine pseudoephedrine formulation and its preparation | |
| CN1857495A (en) | Compound chinese preparation for treating pain symptom and its preparing process | |
| CN1228079C (en) | Oral medicine for treating child restless syndrome | |
| CN1283300C (en) | Chinese traditional medicine composition for treating diabetes and preparation method thereof | |
| CN1268327C (en) | Brufen arginine pseudoephedrine hydrochloride compound formulation | |
| CN1799603A (en) | Chinese traditional medicine composition for treating rheumatic or rheumatoid disease and preparation method thereof | |
| CN101032540A (en) | Medicine composition for curing arthritis and the preparing method and purpose thereof | |
| CN1562271A (en) | Medication for treating primary disease of purpura haemorhagica and preparation method | |
| CN1273137C (en) | Compound prepn. contg. Brufen arginine codeine | |
| CN1586586A (en) | Chinese medicine preparation for treating urinary system infection and its preparing method | |
| CN1293895C (en) | Oral disintegration tablet for laryngopathy and its preparing method | |
| CN1857368A (en) | Medicine composition for treating diabetes | |
| CN100336506C (en) | Orally disintegrating tablet of phentolamine mesylate and its preparation method | |
| CN1218692A (en) | Novel Anti-spasmodic composition and process for manufacture thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: CHINA RESOURCES SANJIU MEDICAL + PHARMACEUTICAL CO Free format text: FORMER OWNER: CHINA PHARMACEUTICAL UNIVERSITY Effective date: 20110418 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 210009 NO. 24, TONGJIA LANE, NANJING CITY, JIANGSU PROVINCE TO: 518029 NO. 1026, BEIHUAN AVENUE, YINHU CROSSING, SHENZHEN CITY, GUANGDONG PROVINCE |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20110418 Address after: 1026 No. 518029 Guangdong province Shenzhen Yinhu North Road intersection Patentee after: CHINA RESOURCES SANJIU MEDICAL & PHARMACEUTICAL Co.,Ltd. Address before: Nanjing City, Jiangsu Province, Tong Lane 210009 No. 24 Patentee before: China Pharmaceutical University |
|
| CX01 | Expiry of patent term |
Granted publication date: 20061004 |
|
| CX01 | Expiry of patent term |